title: Liver transplantation without steroid induction in HIV-infected patients.
abstract: Until recently, human immunodeficiency virus (HIV) infection was considered an absolute contraindication for liver transplantation in Spain. We present the first 4 cases of liver transplantation (LT) carried out in our center in patients infected with HIV and coinfected by the hepatitis C virus (HCV), immunosuppressed with cyclosporine A (CyA) and basiliximab, but without steroids. The 4 patients were male, with a mean age of 38.25 +/- 4.5 years. Mean time of HIV infection was 114 +/- 62.3 months and all patients were receiving highly active antiretroviral therapy (HAART). HCV genotypes of the 4 patients were 4, 1b, 1b, and 1a. Two patients were classified as Child-Turcotte-Pugh C (10 and 11 points), 1 was B (8 points), and the patient with hepatocellular carcinoma was A (5 points). Immunosuppression consisted of basiliximab and monotherapy with CyA. There were no postoperative infections. With a follow-up of 17 +/- 8 months, all patients are alive. There was only 1 acute rejection episode, and this was solved with steroid pulses. Three patients showed HCV recurrence with enzymatic and histological changes and were treated with interferon and ribavirin. One patient had negative HCV-ribonucleic acid after 6 months of treatment. In conclusion, HIV infection should not be considered an absolute contraindication for liver transplantation. The evolution of this type of patients will probably depend on the HCV infection. Immunosuppression without steroids may reduce opportunistic infection.
authors.affiliation: Liver Transplant Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. arafecas@csub.scs.es
authors.forename: Antonio
authors.initials: A
authors.lastname: Rafecas
authors.forename: Gabriel
authors.initials: G
authors.lastname: Rufí
authors.forename: Juan
authors.initials: J
authors.lastname: Figueras
authors.forename: Juan
authors.initials: J
authors.lastname: Fabregat
authors.forename: Xavier
authors.initials: X
authors.lastname: Xiol
authors.forename: Emilio
authors.initials: E
authors.lastname: Ramos
authors.forename: Jaime
authors.initials: J
authors.lastname: Torras
authors.forename: Laura
authors.initials: L
authors.lastname: Lladó
authors.forename: Teresa
authors.initials: T
authors.lastname: Serrano
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000077552:Basiliximab; D000075202:Contraindications; D016572:Cyclosporine / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013030:Spain; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D013256:Steroids; D016572:Cyclosporine; D000077552:Basiliximab